Belgian nuclear medicine products firm Ion Beam Application (IBA) of Louvain-la-Neuve is reporting that a trial date of February 27, 2007, has been set in Los Angeles on the remaining claims asserted against IBA by Optivus Technology of Loma Linda, CA, and Loma Linda University Medical Center.
In November a federal court affirmed the summary judgments in favor of IBA on all patent issues and most nonpatent issues, the company said. The case also was remanded for trial on certain issues of unfair competition that relate to the University of Florida procurement process that led to the selection of IBA to build a proton beam treatment center in Jacksonville, FL.
IBA maintains that it does not infringe on any patents in the suit and did not compete with Optivus unfairly in connection with the UF contract matter.
In other IBA news, the company has entered into an agreement through its pharmaceutical business unit, IBA Molecular, with Wilex of Munich, Germany, to radiolabel Wilex's antibody WX-G250 with iodine-124, and will distribute the PET agent to clinical trial sites worldwide.
The partnership will enable 10 cancer centers to participate in clinical trials with CA9-SCAN. An earlier study found that a positive result with CA9-SCAN could be confirmed as clear cell renal carcinoma all cases. If approved, the new product could improve treatment planning for patients suspected of kidney cancer.
By AuntMinnie.com staff writers
December 21, 2006
Related Reading
IBA starts shipments from new Italian facility, December 11, 2006
IBA to supply technology for French proton therapy project, November 20, 2006
IBA inks SAIC-Frederick deal, debuts new radionuclides, October 2, 2006
IBA shows financial gains in Q2, September 18, 2006
IBA to deliver cyclotron facility to Turkey, August 29, 2006
Copyright © 2006 AuntMinnie.com
